Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Wallace Rivers who wrote (27918)	2/6/1999 11:44:00 AM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

It's my impression that LGND has put together a strong sales force. Most of LGND's senior management came from the large pharmas, so they should have a good understanding of what it takes to sell drugs. With the number of FDA approved drugs growing to 4-6 in the next 12-15 months, LGND's new US sales force (as well as the one being formed in Europe), will have a number of new and exciting developments to pass onto physicians. Traditional valuations are usually based on profits, and LGND's profits are not expected until the last quarter of this year. After that, earnings growth is expect to be quite strong, which should help LGND achieve its pricing potential. As Bear Stearns indicated on Wednesday, Biotechs traditionally make their biggest price moves right after drugs are approved, and David Molowa did not expect LGND to be an exception.